Survival outcomes of low-dose and high-dose bevacizumab front-line maintenance in advanced high-grade serous ovarian cancer: a propensity score-matched real-world study.

Front Oncol · 2026 · PMC13368989 · PMID 42459309

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceP = 0.060so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

Bevacizumab dose showed a trend toward inferior PFS in the low-dose group but did not reach statistical significance in univariate analysis (HR = 1.24, 95%CI 0.98-1.57, P = 0.060).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.